2015
Multiple sclerosis—a quiet revolution
Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis—a quiet revolution. Nature Reviews Neurology 2015, 11: 134-142. PMID: 25686758, PMCID: PMC4556342, DOI: 10.1038/nrneurol.2015.14.Peer-Reviewed Original ResearchConceptsTreatment optionsMajor unmet medical needMultiple sclerosis susceptibilityUnmet medical needNeural tissue injuryGenetic variantsMS therapeuticsAcetate therapyMS riskInflammatory aspectsMultiple sclerosisAutoimmune diseasesTreatable diseaseTissue injuryIndividual patientsDisease evolutionClinical phenotypeMedical needPatientsDisease susceptibilityDiseaseGenetic componentSclerosisIFNOptions
2010
CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis
Bronson PG, Caillier S, Ramsay PP, McCauley JL, Zuvich RL, De Jager PL, Rioux JD, Ivinson AJ, Compston A, Hafler DA, Sawcer SJ, Pericak-Vance MA, Haines JL, Consortium T, Hauser S, Oksenberg J, Barcellos L. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Human Molecular Genetics 2010, 19: 2331-2340. PMID: 20211854, PMCID: PMC2865376, DOI: 10.1093/hmg/ddq101.Peer-Reviewed Original ResearchConceptsClass II transactivator geneMultiple sclerosisPresence of HLAMHC class II transactivator geneMS risk alleleClass II MHCLogistic regression analysisG promoter variantPromoter variantsMS riskAntigen presentationII MHCIncrease riskRisk allelesMulti-stage investigationRs4774Important transcription factorSclerosisRegression analysisHLARiskStage 1Stage 2Transactivator geneAssociation
2009
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score
De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P, the steering committees of the BENEFIT B, Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler D, Karlson E. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. The Lancet Neurology 2009, 8: 1111-1119. PMID: 19879194, PMCID: PMC3099419, DOI: 10.1016/s1474-4422(09)70275-3.Peer-Reviewed Original ResearchConceptsWeighted genetic risk scoreEpstein-Barr virusHealth Study IMultiple sclerosisC-statisticRisk factorsGenetic risk scoreImmune responseRisk scoreNurses' Health Study IDiagnosis of MSNon-genetic risk factorsHigh-risk individualsMultiple sclerosis susceptibilityEnvironmental risk factorsGenetic risk factorsNHS cohortDerivation cohortTherapeutic trialsMS riskProspective studyClinical algorithmImportant clinical applicationsHigher oddsSusceptibility loci
2008
Integrating risk factors
De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors. Neurology 2008, 70: 1113-1118. PMID: 18272866, DOI: 10.1212/01.wnl.0000294325.63006.f8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodiesBiomarkersCase-Control StudiesComorbidityEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeHerpesvirus 4, HumanHeterozygoteHLA-DR AntigensHLA-DRB1 ChainsHumansMiddle AgedMultiple SclerosisRisk FactorsConceptsMultiple sclerosisHuman leukocyte antigenAntibody titersRisk factorsDR15 alleleEpstein-Barr virus (EBV) antibody titersAge-matched healthy womenRisk of MSEpstein-Barr virus nuclear antigen 1Independent risk factorVirus antibody titersCase-control studyNuclear antigen 1Healthy womenMS riskLeukocyte antigenRelative riskGenetic susceptibilityAntigen 1TitersWomenSclerosisRiskDR15Association